Loading
Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.
Ficlatuzumab (AV-299) is a monoclonal antibody developed by AVEO Pharmaceuticals. The sponsor describes its target as HGF (hepatocyte growth factor), which OnCo does not yet have a target page for. The sponsor states: A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab. ClinicalTrials.gov describes the intervention as: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06064877 (A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma), in head and neck squamous cell carcinoma. The largest, NCT06064877, plans to enrol 410 participants with primary completion expected 2027-08. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab.
1.Ficlatuzumab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ficlatuzumab" OR ABSTRACT:"Ficlatuzumab" OR TITLE:"AV-299" OR ABSTRACT:"AV-299") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ficlatuzumab, not a curated reading list.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.